European Society of Gynaecological Oncology

HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, November 9, 2023
Hepatocyte, Prostate-specific antigen, Research, Trial of the century, IND, PSA, Infection, Hepatitis, Pembrolizumab, Head, HIV, Liver, KRAS, Arenavirus, Prostate cancer, Gilead Sciences, Journal, CPI, Development, Gilead, Lung, PAP, Oncology, Serum, Safety, European Society of Gynaecological Oncology, Cancer, Patient, Administration, HBV, The Journal of Infectious Diseases, Investigational New Drug, Pharmaceutical industry, Clothing, Vaccine, Reinsurance

With these encouraging data, we are busy finalizing plans for the randomized trial expected to begin next year,” said Joern Aldag, Chief Executive Officer at HOOKIPA Pharma.

Key Points: 
  • With these encouraging data, we are busy finalizing plans for the randomized trial expected to begin next year,” said Joern Aldag, Chief Executive Officer at HOOKIPA Pharma.
  • Enrollment continued in the ongoing Phase 1/2 study ( NCT05553639 ) of HB-300 for the treatment of advanced prostate cancer.
  • HB-300 is an arenaviral immunotherapy that targets two well-defined self-antigens of prostate cancer, prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA).
  • The decrease was primarily attributable to cash used in operating activities, partly offset by funds resulting from the follow-on financing in June 2023.

EDAP Announces Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
University of Zurich, AAGL, Hospital, EUR, USD, Overalls, Cleveland Clinic, International Symposium on Endovascular Therapy, Operating cost, EDT, Teaching hospital, University of Florida, Icahn School of Medicine at Mount Sinai, EDAP, League of European Research Universities, Prostate cancer, DACH, League, Marketing, Immunotherapy, University, Investment, Patient, TMS, Congress, Conference, Endo, Research, Growth, SEP, European Society of Gynaecological Oncology, Total, Poster, Lithotripsy, Mount Sinai Hospital, Randomized controlled trial, Pharmaceutical industry, Medical imaging, Film industry, Video game, Lithium, Medicine, Distribution, Urology

- Strong Q3 2023 U.S. Focal One® HIFU procedure growth of +150% year-over-year -

Key Points: 
  • - Strong Q3 2023 U.S. Focal One® HIFU procedure growth of +150% year-over-year -
    - Announces immunotherapy clinical research collaboration with Mount Sinai, Department of Urology -
    - Company to host conference call and webcast today, Thursday, November 9th at 8:30 am EDT -
    LYON, France, November 9, 2023 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited financial results for the third quarter ending September 30, 2023.
  • The decrease was driven by 1 Focal One system sold in the third quarter 2023 versus 3 systems sold in the third quarter of 2022.
  • Operating loss for the third quarter of 2023 was EUR 5.6 million (USD 6.0 million), compared to an operating loss of EUR 2.1 million (USD 2.2 million) in the third quarter of 2022.
  • A conference call and webcast to discuss the third quarter 2023 financial results will be hosted Ryan Rhodes, Chief Executive Officer, François Dietsch, Chief Financial Officer and Ken Mobeck, Chief Financial Officer of the U.S. subsidiary, today, Thursday, November 9th, 2023, at 8:30am EDT.

Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Wednesday, November 8, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Standard of care, NSCLC, Food, Pancreas, Anastrozole, Regulatory affairs, Ovarian cancer, GAAP, Pancreatic Cancer Action Network, Paclitaxel, Accelerated approval (FDA), ORR, European Network of Transmission System Operators for Electricity, Safety, Cancer, Therapy, Investment, Patient, General Administration of Sport of China, Verastem Oncology, Topotecan, Conference, Bank statement, Clinical trial, FRAME, Travel, Letrozole, RAMP, FDA, SOC, AACR, RAS, Research and development, The Annual Global Orgasm for Peace, GOG, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, KRAS, Senior, Pharmacokinetics, European Society of Gynaecological Oncology, Lung cancer, Table, Diagnosis, Pharmaceutical industry, Bank, Finance

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the third quarter ending September 30, 2023 and highlighted recent progress.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the third quarter ending September 30, 2023 and highlighted recent progress.
  • Verastem Oncology ended the third quarter of 2023 with cash, cash equivalents and investments of $165.7 million.
  • Research & development expenses for the 2023 Quarter were $13.9 million, compared to $11.3 million for the 2022 Quarter.
  • Selling, general & administrative expenses for the 2023 Quarter were $7.4 million, compared to $6.4 million for the 2022 Quarter.

Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates

Retrieved on: 
Tuesday, November 7, 2023
Research, Transgender hormone therapy, American Association of Clinical Endocrinologists, Event, Child, LUMO, Pediatric endocrinology, Therapy, City of Hope National Medical Center, Rare, IGFBP3, Mother, MD, Quarter, SDS, Endocrine Society, Clinical trial, PEM, KOL, Lumos, University, Serum, University of Chile, Political moderate, European Society of Gynaecological Oncology, Growth hormone, Investment, Consistency, AHV, Silviculture, Pharmaceutical industry, Birth control, Endocrinology

AUSTIN, Texas, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that topline results met primary and secondary endpoints for its Phase 2 Dose-Finding OraGrowtH210 Trial and Phase 2 Pharmacokinetic/Pharmacodynamic (PK/PD) OraGrowtH212 Trial evaluating oral LUM-201 for subjects with moderate pediatric growth hormone deficiency (PGHD) who screened PEM-positive utilizing Lumos Pharma’s predictive enrichment marker (PEM) strategy. Lumos also announced its financial results for the quarter ended September 30, 2023.

Key Points: 
  • Lumos also announced its financial results for the quarter ended September 30, 2023.
  • The Company expects cash use of approximately $9.0 to $10.0 million in the fourth quarter of 2023.
  • Net Loss – The net loss for the quarter ended September 30, 2023 was $8.3 million compared to a net loss of $7.3 million for the same period in 2022.
  • Lumos Pharma ended the third quarter 2023 with 7,914,582 shares outstanding.

Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023
Research, Sale, Arm, Equity method, Bayer, ATM, ESMO, LRRK2, RPF, Enrollment, Greyhawk, Income tax, CTA, Prostate cancer, Exercise, Development, PROTAC, Pfizer, Clinical trial, BCL6, Neuroscience, CDK4, Breast cancer, State Administrative Expenses, ARVN, Genentech, European Society of Gynaecological Oncology, Investment, AR, Patient, Administration, Everolimus, Pharmaceutical industry, Medical imaging, Dietary supplement, Life insurance, IND, Gaius Papirius Carbo Arvina

NEW HAVEN, Conn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • Research and Development Expenses: Research and development expenses were $85.9 million for the quarter ended September 30, 2023, as compared with $77.5 million for the quarter ended September 30, 2022.
  • General and Administrative Expenses: General and administrative expenses were $22.6 million for the quarter ended September 30, 2023, as compared with $20.0 million for the quarter ended September 30, 2022.
  • Revenues: Revenues were $34.6 million for the quarter ended September 30, 2023, as compared with $33.2 million for the quarter ended September 30, 2022.
  • Net Loss: Net loss was $64.0 million for the quarter ended September 30, 2023, as compared with $66.2 million for the quarter ended September 30, 2022.

Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 7, 2023
Research, European Organisation for Research and Treatment of Cancer, Treatment, Ipilimumab, Record, Melanoma, Viral load, OS, Neoplasm, PIWIL1, BRAF, Sale, ESMO, EORTC, HIV, Circulating tumor DNA, World Games, The New England Journal of Medicine, Cancer, Patient, DNA, Nivolumab, Congress, CTA, MAD, Insming, Oncology, RFS, PRAME, Nivolumab/relatlimab, TCR International, European Society of Gynaecological Oncology, IND, SVP, TCR, Gastrointestinal cancer, European Society for Medical Oncology, Observation, Senior, Infection, Book, James A. Schlipmann Melanoma Cancer Foundation, HBV, Pharmaceutical industry, Cryptocurrency, Medical imaging, USD, IMC, Immunocore

& ROCKVILLE, Md., US, 07 November 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • & ROCKVILLE, Md., US, 07 November 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.
  • Commercial sales have increased in the United States and European countries, including France, Germany and Italy, during the third quarter.
  • Since the beginning of 2023, we have launched KIMMTRAK in Austria, Israel, Italy, Finland, Switzerland and Belgium, and have recently reached price agreements with Canada and Australia.
  • Cash and cash equivalents were £364.0 million ($444.5 million) as of September 30, 2023, compared to £332.5 million as of December 31, 2022.

FibroGen Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 6, 2023
Sale, JDE, AstraZeneca, LAPC, Pancreatic Cancer Action Network, American Society of Nephrology, CD46, Poster, Society, Bank statement, Chronic kidney disease, Immunotherapy, Growth, ADC, Interest, ASN, Webcast, Abstract, Pamrevlumab, Pancreatic cancer, Oncology, Anemia, CKD, European Society of Gynaecological Oncology, Investment, Patient, CIA, SAN, Shanda, Pharmaceutical industry, Video game, Vaccine, Roxadustat

Total revenue for the third quarter of 2023 was $40.1 million, as compared to $15.7 million for the third quarter of 2022, an increase of 155% year over year.

Key Points: 
  • Total revenue for the third quarter of 2023 was $40.1 million, as compared to $15.7 million for the third quarter of 2022, an increase of 155% year over year.
  • Restructuring charge for the third quarter of 2023 was $12.6 million, or $0.13 impact to net loss per basic and diluted share, resulting from the reduction in U.S. workforce announced in July 2023.
  • The distribution entity jointly owned by AstraZeneca and FibroGen is not consolidated into FibroGen’s financial statements.
  • FibroGen will host a conference call and webcast today, Monday, November 6, 2023, at 5:00 PM Eastern Time to discuss financial results and provide a business update.

Kura Oncology Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
CR, Research, Mirati Therapeutics, NSCLC, AACR, Kura, Acute myeloid leukemia, FTI, Hematology, Mirati, Conference, KMT2A, CRH, KRAS, Azacitidine, HRAS, HNSCC, Disease, ID, Marketing, Webcast, Cancer, KURA, Oncology, Venetoclax, Mixed-phenotype acute leukemia, FLT3, Safety, European Society of Gynaecological Oncology, Renal cell carcinoma, Investment, Patient, Therapy, AML, Pharmaceutical industry, Bank, Video game, Cryptocurrency

ET –

Key Points: 
  • ET –
    SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported third quarter 2023 financial results and provided a corporate update.
  • Research and development expenses for the third quarter of 2023 were $29.3 million, compared to $25.0 million for the third quarter of 2022.
  • General and administrative expenses for the third quarter of 2023 were $13.1 million, compared to $11.6 million for the third quarter of 2022.
  • ET / 1:30 p.m. PT today, November 2, 2023, to discuss the financial results for the third quarter 2023 and to provide a corporate update.

ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Novartis Institute for Tropical Diseases, Research, NSCLC, Acute myeloid leukemia, IMGN, Food, PIN, Biomedical Research, ImmunoGen, European Medicines Agency, Doctor of Philosophy, Medicine, Capital expenditure, New Drug Application, Takeda Pharmaceutical Company, Marketing, BPDCN, ESGO, US Foods, Azacitidine, European Society of Gynaecological Oncology, EMA, ORR, NDA, Safety, Cancer, György Enyedi (geographer), Patient, National Medical Products Administration, Eli Lilly and Company, MAA, Congress, Mirvetuximab soravtansine, Blastic plasmacytoid dendritic cell neoplasm, ASH, Growth, ADC, Spacecraft, FDA, NMPA, PROC, University Clinical Centre in Gdańsk, Society, Senior, Inc., Huadong Medicine, AML, PARP, Vaccine, Pharmaceutical industry, Dietary supplement, Takeda

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023.

Key Points: 
  • ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023.
  • We also continued to monitor the NSCLC cohort with IMGC936 and advanced dose escalation with IMGN151, our second-generation ADC targeting FRα.
  • Selling, general and administrative expenses were $37.7 million for the quarter ended September 30, 2023 compared to $33.6 million for the quarter ended September 30, 2022.
  • Capital expenditures were $1.6 million and $1.1 million for the first nine months of 2023 and 2022, respectively.

Oncoinvent Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for Radspherin® in Ovarian Cancer Patients

Retrieved on: 
Tuesday, October 31, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, IND, Ovarian cancer, Food, Progression-free survival, ESGO, Colorectal cancer, Congress, PFS, University Clinical Centre in Gdańsk, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, European Society of Gynaecological Oncology, Clinical trial, U.S. FDA, Safety, Patient, Pharmaceutical industry

This represents the second U.S. FDA IND clearance for Radspherin®, as last week, the company also announced an IND acceptance for Radspherin® in patients with peritoneal carcinomatosis from colorectal cancer.

Key Points: 
  • This represents the second U.S. FDA IND clearance for Radspherin®, as last week, the company also announced an IND acceptance for Radspherin® in patients with peritoneal carcinomatosis from colorectal cancer.
  • “We are thrilled to announce the IND clearance for this phase 2b study of Radspherin®, allowing for inclusion of patients in the first-line treatment setting of ovarian cancer,” said Anders Månsson, Chief Executive Officer of Oncoinvent.
  • “This IND clearance comes in succession to the IND clearance of Radspherin® in colorectal cancer patients, announced recently.
  • It is a randomized controlled phase 2b trial, assessing efficacy and safety of Radspherin® in patients with peritoneal metastasis from ovarian cancer.